Share on LinkedInShare on LinkedIn

ARTICLE · 08 NOVEMBER 2012

Obviousness-Type Double Patenting Requires A Reason To Modify With A Reasonable Expectation Of Success

Addressing the issue of obviousness-type double patenting, the U.S. Court of Appeals for the Federal Circuit reaffirmed its earlier rulings that obviousness must be judged by whether the differences in subject matter between the new claim and the earlier claim are patentably distinct.

United StatesIntellectual Property

Addressing the issue of obviousness-type double patenting, the U.S. Court of Appeals for the Federal Circuit reaffirmed its earlier rulings that obviousness must be judged by whether the differences in subject matter between the new claim and the earlier claim are patentably distinct.  Eli Lilly and Co. et al. v. Teva Parenteral Medicines et al., Case Nos. 11-1561, -1562 (Fed. Cir., Aug. 24, 2012) (Lourie, J.). 

The appeal arose from the filing of an Abbreviated New Drug Application (ANDA) by Teva for regulatory approval of the anticancer agent pemetrexed.  At trial, Teva conceded infringement of U.S. Patent No. 5,344,932, but argued that the patent was invalid for obviousness-type double patenting based on two parent references—a predecessor to pemetrexed shown in U.S. Patent Nos. 5,028,608 and an intermediate in making pemetrexed shown in U.S. Patent No. 5,248,775.  The district court found the patent was not invalid, ruling that one of ordinary skill in the art

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from